Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt had restricted stock units vest into 41,668 shares of common stock on the transaction date. The company withheld 17,701 shares to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Vogt directly held 553,505 common shares and 125,007 remaining RSUs that will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported routine equity compensation activity. On June 1, 2026, 5,469 restricted stock units (RSUs) vested and converted into the same number of common shares. Of these, 2,508 shares were withheld by the company to cover mandatory tax obligations, which the filing specifies was not an open-market sale. After these transactions, Puri directly holds 242,191 shares of common stock and 16,409 RSUs from the referenced grant, which will continue to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On the transaction date, RSUs covering 8,790 shares of common stock vested, and an equivalent number of common shares were issued upon conversion of the RSUs.
To cover mandatory tax withholding on this vesting, 4,473 common shares were withheld by the company at a price of $3.96 per share, which the filing notes was not an open market sale. After these transactions, the reporting person directly held 136,274 shares of common stock and 26,369 RSUs, with the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Operating Officer Igor Bilinsky reported routine equity compensation activity. On the transaction date, 8,790 restricted stock units (RSUs) vested into an equal number of common shares. The company withheld 4,473 shares at $3.96 per share to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Bilinsky directly held 134,556 shares of common stock and 26,369 RSUs that will continue to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Kirby Daniel Gordon reported routine equity compensation activity. On May 11, 2026, 10,000 restricted stock units (RSUs) vested and converted into common stock, with 2,435 shares withheld by the company to cover mandatory tax obligations rather than sold on the market.
After these transactions, Gordon directly holds 146,946 shares of common stock and 70,004 RSUs, which the filing states will vest in equal quarterly installments. The activity reflects compensation vesting and tax withholding, not open-market buying or selling.
State Street Corporation reports beneficial ownership of 17,448,108 shares of Iovance Biotherapeutics common stock, representing 4.2% as of 03/31/2026.
The filing shows shared voting power of 16,532,266 shares and shared dispositive power over 17,448,108 shares. The Schedule 13G lists several State Street advisory subsidiaries as the reporting entities. The signature block is dated 05/12/2026.
Iovance Biotherapeutics reported first quarter 2026 revenue of about $71.4 million, approximately 45% higher than a year earlier, reflecting strong demand for Amtagvi. The company issued revenue guidance of $86–88 million for the second quarter and $350–370 million for full-year 2026, signaling expectations for continued growth.
Iovance remains unprofitable, with a net loss of $79.0 million and a loss per share of $0.19, though both improved versus 2025. Management highlighted internal manufacturing efficiencies, cost reductions, and a 40% confirmed objective response rate in metastatic serous endometrial cancer as it advances multiple TIL therapy trials. Cash, cash equivalents, and investments totaled $313.4 million as of March 31, 2026.
Iovance Biotherapeutics reported Q1 2026 net product revenue of $71.4 million, primarily from its TIL therapy Amtagvi and IL‑2 product Proleukin, up from $49.3 million a year earlier. Amtagvi contributed $60.2 million and Proleukin $11.2 million.
The company posted a net loss of $79.0 million, improved from a $116.2 million loss in Q1 2025, as operating expenses and stock-based compensation declined. Cash, cash equivalents, short‑term investments and restricted cash totaled $319.4 million, and management believes this is sufficient to fund planned operations for at least the next twelve months while it continues commercial expansion and late‑stage trials in melanoma and other solid tumors.
Iovance Biotherapeutics is asking stockholders to approve seven proposals at its 2026 virtual-only annual meeting on June 10, 2026. Holders of 446,502,396 shares of common stock as of April 15, 2026 can vote online, by phone, mail, or during the webcast.
Stockholders will vote on re-electing six directors, an advisory “say on pay” for named executive officers, and how often to hold future say-on-pay votes. They will also consider ratifying Ernst & Young LLP as auditor for 2026, adding 1,000,000 shares to the 2020 Employee Stock Purchase Plan, increasing authorized common stock from 500,000,000 to 650,000,000 shares, and a potential adjournment to solicit more proxies if Proposal 6 lacks support.